An oral Wegovy and resolved shortages have sharpened one of 2026's most practical questions: FDA-approved or compounded? The difference is not just price. Here is what changed, and what it means for sourcing safely.
As the Wegovy pill launched in January 2026 and FDA-declared shortages of branded GLP-1s remained resolved, the gap widened between FDA-approved GLP-1 products and compounded versions. Compounded GLP-1s are not FDA-approved, and their legal availability has narrowed.
The arrival of an oral option expanded how consumers can access GLP-1 therapy — but it also brought the access-and-safety question into sharper focus. During the 2022-onward shortages of semaglutide and tirzepatide, compounding pharmacies legally filled supply gaps, and many telehealth platforms built businesses around lower-cost compounded versions. With shortages declared resolved, that pathway has narrowed considerably: compounded copies of commercially available GLP-1s are generally not permitted except in limited, documented circumstances.
The core distinction consumers should understand: FDA-approved products (such as branded semaglutide and tirzepatide) undergo pre-market review for safety, efficacy, and manufacturing quality. Compounded versions do not go through that same approval process — "same active ingredient" does not guarantee equivalent dosing accuracy, purity, or outcomes, and regulators have flagged adverse events tied to dosing errors with some compounded products. January 2026 consumer coverage emphasized comparing these access models carefully rather than defaulting to the cheapest option found online.
For the injectable-curious consumer, 2026 is a year to be precise about sourcing. The headline efficacy figures often cited in marketing come from trials of branded products (for example, roughly 15% mean weight loss with semaglutide in STEP and 16-22.5% with tirzepatide in SURMOUNT) — not from compounded versions or specific telehealth programs. Matching expectations to what was actually studied, and choosing licensed prescribers and authorized products, is the throughline of credible guidance.